Murray Yule is a board certified medical oncologist who trained in the United Kingdom and Houston Texas. He gained his Phd in anticancer therapeutics at the University of Newcastle and he is a member of the Royal College of Physicans of the United Kingdom.Murray has more than seventeen years’ experience in the Pharma Industry and Biotechnology in Europe and has a broad experience of the development of early anticancer therapeutics across the globe having successfully filed multiple INDs and CTA applications exploring previously unrecognised cancer targets and published more than twenty papers in this field. Whilst working at Eisai Murray led the team that successfully achieved global market approval of eribulin for the treatment of metastatic breast cancer. As the Medical Director of Astex Therapeutics Murray was instrumental in its merger with Supergen Inc and ultimately its acquisition by Otsuka Pharmaceutical. Previously when working with BergenBio ASA management team Murray contributed to its successful IPO on the Norwegian exchange in 2017 followed by a further round of US investment in 2018.As a biotechnology medical officer Murray has successfully formed and driven translational and clinical collaborations with larger pharma including Novartis (small molecules leading to the development of ribociclib) and Merck (Immunoncology).